Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Selinexor vs. SOC in penta-exposed MM: STORM & MAMMOTH analysis

Luciano Costa • 8 Dec 2019
ASH 2019
Multiple Myeloma Selinexor
MAMMOTH STORM

Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, discusses the analysis of selinexor plus dexamethasone (Sd) vs. conventional care for triple class refractory, penta-exposed multiple myeloma in terms of overall survival (OS). This compared data from the STORM trial (NCT02336815) with real world data from the retrospective MAMMOTH study. While not an replacement for a prospective, randomized trial, this analysis suggested improved OS with Sd vs. conventional care in this group. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Luciano Costa

1:45
Challenges for community clinicians treating multiple myeloma
Luciano Costa • 11 Dec 2023
2:02
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma
Luciano Costa • 11 Dec 2023
2:40
Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myeloma
Luciano Costa • 11 Dec 2023
3:38
Outcomes for patients with multiple myeloma who have had first-line monoclonal antibody exposure
Luciano Costa • 11 Dec 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals